With the flurry of device company M&A activity, some analysts anticipate future spine deals to occur, according to The Street.
Here are seven things to note:
1. Jeffries analysts expect Warsaw, Ind.-based Zimmer Biomet to continue to grow in the latter half of 2016. The company's overall revenue growth proved 2.5 percent better than analysts' estimates.
2. Zimmer Biomet also reported second quarter revenue of $1.93 billion, which exceeded Wall Street analysts' expectations of $1.9 billion.
3. The company's continued growth is only elevated by its recent M&A activity. Zimmer Biomet acquired LDR Holding for $1 billion, with a deal set to close in the third quarter.
4. San Diego-based NuVasive, Lewisville, Texas-based Orthofix and Belgrade, Mont.-based Xtant Medical may pose as attractive M&A targets, according to The Deal's Sarah Pringle.
5. On the heels of Zimmer Biomet, NuVasive represents another major player in the spine space. But the company is focused more on buying then selling in 2016, buying Ellipse Technologies for $410 million in January.
6. In June, NuVasive acquired Biotronic NeuroNetwork for $98 million.
7. Some analysts point to NuVasive's executive leadership as equipped to handle a merger or acquisition if approached by another company, however.